EpiCypher and New England Biolabs Expand Strategic Partnership to Advance Epigenomics Research
DURHAM, N.C. and IPSWICH, Mass., May 19, 2026 /PRNewswire/ — EpiCypher® and New England Biolabs® (NEB®) today announced an expanded strategic partnership to co-develop next-generation tools for epigenomics research. Building on a successful track record of collaboration, the partnership will accelerate the creation of innovative technologies that advance understanding of gene regulation, chromatin biology, and disease mechanisms.
The partnership combines EpiCypher’s strengths in chromatin biology, assay development, and epigenomic profiling with NEB’s leadership in enzyme innovation, molecular biology, and reagent production to deliver high-performance solutions that enable deeper, more precise insights into epigenetic regulation. NEB has a history of applying its enzymology expertise to such applications and has already developed numerous novel approaches for the study of DNA methylation, hydroxymethylation, the epitranscriptome, chromatin accessibility, and chromatin interactions.
